Which First-Line Treatment Is Most Effective in Advanced Liver Cancer?
In this article
🍃 Which Treatment Preserves Both Survival and Quality of Life in Advanced Liver Cancer?
First-line treatment for unresectable or advanced hepatocellular carcinoma (HCC) has entered a new era that considers not only survival but also health-related quality of life (HR-QoL) . On August 14, 2025, JAMA Oncologypublished a network meta-analysis by Celsa and colleagues showing that atezolizumab + bevacizumab particularly offers the best balance between these two goals.
1. Introduction: A Changing Paradigm
🌍 A global problem: HCC is a leading cause of cancer death worldwide. As of 2025, annually, more than 1 million new cases are expected.
🔄 Historical standard: Sorafenib was the only treatment option for more than 10 years. Immunotherapy combinations, however, have changed the landscape.
2. Beyond Survival: The Role of Quality of Life
In cancer treatment, how people live has gained importance alongside how long they live. Patient-reported outcomes (PROs) now have substantial prognostic value alongside clinical measures. As Prof. Dr. Mustafa Özdoğan puts it:
3. Meta-Analysis Findings
- 9 phase III studiesincluding a total of 6,425 patients were examined.
- Atezolizumab + Bevacizumab had the highest probability of preserving quality of life:
- Global health status: 85%
- Abdominal swelling: 95%
- Jaundice: 89%
- Pain: 86%
- Tislelizumabperformed best for physical functioning (96%) and fatigue.
📊 In summary: When survival + quality of life were considered together, atezolizumab + bevacizumab outperformed the other treatments across all domains.
4. Clinical Implications
In light of these data, atezolizumab + bevacizumab in advanced HCC is:
- ✅ The most balanced treatment option,
- ✅ A tangible example of patient-centered care,
- ✅ Consistent with international guidelines (ASCO 2024, NCCN 2025, ESMO 2025).
5. Conclusion
🔑 Message: The best treatment for advanced liver cancer not only extends life but also preserves quality of life. The network meta-analysis strongly supports atezolizumab + bevacizumab as the regimen that best achieves this balance.
⚠️ Side-Effect Profile and Management
The side-effect profiles of TKIs and immunotherapies directly affect not only clinical efficacy but also patients’ quality of life and adherence to treatment.
| Side Effect | Sorafenib | Lenvatinib |
|---|---|---|
| Hand–Foot Skin Reaction (HFSR) | High | Moderate |
| Fatigue | Common, dose-limiting | Common, dose-limiting |
| Hypertension | Moderate | Higher incidence |
| Diarrhea | Common | Common |
🦶 Hand–Foot Skin Reaction (HFSR): Can seriously impair walking and daily activities (e.g., fastening buttons).
Management: Avoid friction, use moisturizers, cool-water baths, comfortable shoes, and topical steroids.
😴 Fatigue: One of the most common dose-limiting toxicities of TKIs.
Management: Sleep hygiene, gentle exercise, and dose reduction if necessary.
🫀 Hypertension: More frequent with lenvatinib than sorafenib.
Management: Regular blood pressure monitoring, antihypertensive medications.
💧 Diarrhea: Common with all TKIs.
Management: Dietary modification, fluids, and antidiarrheals such as loperamide.
🔎 The Patient Perspective: Adverse effects create psychological and social pressures as well as physical burdens. Qualitative studies show that patients experiencing HFSR or severe fatigue may question the treatment’s value.
🌍 Clinical Impact and the Future of HCC Treatment
| Guideline | Recommended First-Line Treatments |
|---|---|
| ASCO 2024 | Atezolizumab + Bevacizumab, Durvalumab + Tremelimumab (strong recommendation, moderate-to-high evidence level) |
| NCCN v1.2025 | Immunotherapy-based combinations preferred; TKIs (lenvatinib, sorafenib) as alternatives |
| ESMO 2025 | Atezolizumab + Bevacizumab standard; Durvalumab + Tremelimumab a suitable option; TKIs only if contraindications are present |
📌 5.1. Alignment with International Guidelines
The Celsa et al. meta-analysis findings fully align with current ASCO, NCCN and ESMO guidelines . Based on strong evidence, the ASCO 2024 update recommends atezolizumab + bevacizumab and durvalumab + tremelimumab as first-line treatments, while NCCN v1.2025 and ESMO 2025 similarly prioritize immunotherapy-based combinations.
🔎 Clinical Message: Immunotherapy-based regimens are now the international standard . TKIs are preferred only when immunotherapy is contraindicated or inaccessible.
🧩 5.2. Critical Factors in Patient Selection
Treatment selection is not a uniform decision. Clinical data must be combined with patient-specific factors in every case.
⚖️ Eligibility Criteria:
- Child-Pugh A liver function
- ECOG performance status 0–1
- Controlled comorbidities
❗ Special Situation: For bevacizumab, high-risk esophageal variceal bleeding is a contraindication and a critical factor in treatment selection.
🔬 5.3. The Evolving Treatment Landscape: Combinations
Research in advanced HCC continues, particularly focusing on combination therapies .
LEAP-002 Study: Although pembrolizumab + lenvatinib did not meet the statistical significance target:
- Median OS: 21.2 months vs 19.0 months
- Duration of response: Encouraging
Note: These results illustrate how difficult it is for new treatments to demonstrate significant differences against effective controls (lenvatinib).
Studies adding agents to atezolizumab + bevacizumab are also ongoing. More refined doublet or triplet combinations may emerge in the future.
🧬 5.4. Biomarkers in Personalized Treatment
The future of HCC treatment rests on biomarker-based personalized medicine as its foundation.
📌 Example Research Areas:
- FGF19 overexpression: May predict response to irpagratinib.
- Prognostic biomarkers: Early identification of patients likely to benefit from Atezolizumab + Bevacizumab.
These developments will enable the approach of ‘the right treatment for the right patient at the right time.’
Summary
🍃 The First-Line Treatment Paradigm in Advanced Liver Cancer
The Celsa et al. network meta-analysis (JAMA Oncology, August 14, 2025) integrates OS + HR-QoL and shows atezolizumab + bevacizumab to be the most balanced option.
- Long term: ~25% of patients at 4 years remain alive
- Later deterioration in QoL domains
Best ranking in physical functioning and fatigue (SUCRA 96%). Potential domain-specific benefit.
- Child-Pugh A liver function
- ECOG 0–1
- Controlled comorbidities
Bevacizumab use: high-risk esophageal variceal bleeding is a major barrier; alternative regimens should be considered.
- HFSR: high (sora), moderate (lenva)
- Fatigue: common, dose-limiting
- Hypertension: lenva > sora
- Diarrhea: common
- Fatigue, flu-like symptoms
- Immune-related events: hepatitis, thyroiditis, etc.
- Management: according to grade, delay/adjust dosing ; steroid-based approach
- HFSR: avoid friction, moisturizers, topical steroids
- HT: regular measurements, antihypertensives
- Diarrhea: fluids + antidiarrheals
- OS: 21.2 months vs 19.0 months (statistical target not met)
- Duration of response: encouraging
- Implication: demonstrating a difference against a strong control arm is difficult
- FGF19 overexpression → targeted therapy research (e.g., irpagratinib)
- For Atezo+Beva, prognostic biomarkers are needed
🔑 Conclusion: First-line treatments should be prioritized for preserving quality of life as well as extending life. In the integrated analysis, atezolizumab + bevacizumab offers the strongest overall balance; durvalumab + tremelimumab is supported by significant OS gains and long-term survival.
Sources
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.